mhurhangee/ep-ind-claims huggingface dataset:
A toner for electrostatic latent image development, wherein the toner is prepared by aggregating, by use of an aggregating agent, fine particles containing a binder resin prepared by microparticulation together with 2 parts by mass of sodium polyoxyethylene lauryl ether sulfate relative to 100 parts by mass of the binder resin, pigment fine particles, and fine particles containing a release agent, to thereby obtain fine particle aggregates, the fine particle aggregates being subsequently coalesced by heating to 65°C, cleaned by using ion-exchange water, dried by using a continuous surface-modifying device, and attached with 2 parts by mass of hydrophobic silica relative to 100 parts by mass of the obtained dried powder, the binder resin is an amorphous polyester obtained from condensation copolymerization of polyoxypropylene (2,2)-2,2-bis(4-hydroxyphenyl)propane / polyoxyethylene (2,0)-2,2-bis(4-hydroxyphenyl)propane / fumaric acid / trimellitic acid in a mole ratio of 25 / 25 / 46 / 4, a number average molecular mass (Mn) is 2,500, a mass average molecular mass (Mw) is 6,500, a molecular mass distribution (Mw/Mn) is 2.6, a softening point is 91°C, a glass transition point (Tg) is 51°C, and an acid value is 15.5 mg KOH/g, the pigment fine particles have an average primary particle diameter of 50 nm or less measured with a particle size distribution analyzer, a Cv value of less than 20% measured with the particle size distribution analyzer, and an average circularity of 0.900 or more confirmed from a TEM image, and the Cv value is defined by the following formula: Cv value = 100 · (standard deviation) / (volume average particle diameter), and the circularity is defined by the following formula: circularity = 4πS/L 2, wherein S is an area and L is a boundary length.
A nucleic acid molecule encoding a chimeric protein for use in treating allergy, wherein the nucleic acid molecule comprises, fused in frame in sequential order: a nucleic acid sequence encoding a signal sequence; a nucleic acid sequence encoding a lumenal domain of a human lysosomal associated membrane protein (LAMP); a nucleic acid sequence encoding an allergen protein, wherein the nucleic acid sequence does not include a naturally-occurring signal sequence of the allergen protein; a nucleic acid sequence encoding a transmembrane domain of a human LAMP; and a nucleic acid sequence encoding a targeting domain of a human LAMP, wherein the human LAMP is selected from human LAMP-1, human LAMP-2, human CD63/LAMP-3, or human DC-LAMP. a nucleic acid sequence encoding a signal sequence; a nucleic acid sequence encoding a lumenal domain of a human lysosomal associated membrane protein (LAMP); a nucleic acid sequence encoding an allergen protein, wherein the nucleic acid sequence does not include a naturally-occurring signal sequence of the allergen protein; a nucleic acid sequence encoding a transmembrane domain of a human LAMP; and a nucleic acid sequence encoding a targeting domain of a human LAMP,
An electromagnetic, EM, coil (114, 118, 200, 400) for position tracking, the EM coil comprising: a core substrate (402, 500, 700) composed of material with a lower density than ferrite or iron, or comprising one or more voids in a body of the core substrate, or being formed as a lattice-like hollow-frame structure to constitute a hollow-core; characterised in that the EM coil further comprises thin metal foil (202, 404, 405, 406) wound around the core substrate along three orthogonal axes, the thin metal foil having a magnetic permeability higher than iron. a core substrate (402, 500, 700) composed of material with a lower density than ferrite or iron, or comprising one or more voids in a body of the core substrate, or being formed as a lattice-like hollow-frame structure to constitute a hollow-core; characterised in that the EM coil further comprises thin metal foil (202, 404, 405, 406) wound around the core substrate along three orthogonal axes, the thin metal foil having a magnetic permeability higher than iron.
A flexible printed circuit board, PCB,, comprising: a metalized via extending through the flexible PCB from a first surface(108, 208) to an opposite second surface (110, 210) of the flexible PCB; a battery in contact with the second surface and covering the metalized via; and the flexible PCB characterized by a conductive light curable epoxy disposed on the first surface over and in the metalized via such that the conductive light curable epoxy contacts and adheres to the battery and provides a conductive path from the battery to the metalized via. a metalized via extending through the flexible PCB from a first surface(108, 208) to an opposite second surface (110, 210) of the flexible PCB; a battery in contact with the second surface and covering the metalized via; and the flexible PCB characterized by a conductive light curable epoxy disposed on the first surface over and in the metalized via such that the conductive light curable epoxy contacts and adheres to the battery and provides a conductive path from the battery to the metalized via.
A combination comprising the following separate components: (i) a compound of Formula I or a pharmaceutically acceptable salt thereof: (5-azacytosine group)-L-(guanine group) wherein L is a phosphorous-containing linker of Formula: wherein, R 1 and R 2 are independently H, OH, an alkoxy group, an alkoxyalkoxy group, an acyloxy group, a carbonate group, a carbamate group, or a halogen; R 3 is H, or R 3 together with the oxygen atom to which R 3 is bound forms an ether, an ester, a carbonate, or a carbamate; R 4 is H, or R 4 together with the oxygen atom to which R 4 is bound forms an ether, an ester, a carbonate, or a carbamate; and X together with the oxygen atoms to which X is bound forms a phosphodiester, a phosphorothioate diester, a boranophosphate diester, or a methylphosphonate diester; and (ii) one or more ancillary therapeutic component(s), wherein said ancillary therapeutic component is a T-cell activating agent; wherein said compound of Formula I, or pharmaceutically-acceptable salt thereof, is for administration before said ancillary therapeutic component. (i) a compound of Formula I or a pharmaceutically acceptable salt thereof: (5-azacytosine group)-L-(guanine group) wherein L is a phosphorous-containing linker of Formula: wherein, R 1 and R 2 are independently H, OH, an alkoxy group, an alkoxyalkoxy group, an acyloxy group, a carbonate group, a carbamate group, or a halogen; R 3 is H, or R 3 together with the oxygen atom to which R 3 is bound forms an ether, an ester, a carbonate, or a carbamate; R 4 is H, or R 4 together with the oxygen atom to which R 4 is bound forms an ether, an ester, a carbonate, or a carbamate; and X together with the oxygen atoms to which X is bound forms a phosphodiester, a phosphorothioate diester, a boranophosphate diester, or a methylphosphonate diester; and (ii) one or more ancillary therapeutic component(s), wherein said ancillary therapeutic component is a T-cell activating agent; wherein said compound of Formula I, or pharmaceutically-acceptable salt thereof, is for administration before said ancillary therapeutic component.
A hearing device, for example a hearing aid, configured to be located at or in an ear of a user, the hearing device comprising • an input unit comprising a multitude of input transducers (M1, M2) for providing respective electric input signals (IN1, IN2) representing sound in an environment of the user; • an output unit comprising an output transducer for providing stimuli perceivable to the user as sound based on said electric input signals (IN1, IN2) or a processed version thereof; • a spatial filter connected to said input unit and to said output unit, and configured to provide a spatially filtered signal (Y BF) based on said multitude of electric input signals (IN1, IN2) and configurable beamformer weights; • a loop gain estimator for estimating a current loop magnitude of a feedback loop defined by a forward path between the input unit and the output unit, and an external feedback path (h1, h2) from said output unit to said input unit, CHARACTERIZED IN THAT said hearing device comprises • a spatial filter controller configured to apply first and/or second different sets (w1p, w2p) of beamformer weights to said multitude of electric input signals (IN1, IN2) in dependence of said estimated current loop magnitude, wherein said first set (w1p) of beamformer weights is applied to provide spatial filtering of sound from said output transducer, and wherein said second set (w2p) of beamformer weights is applied to provide spatial filtering of an external sound field (S ENV). • an input unit comprising a multitude of input transducers (M1, M2) for providing respective electric input signals (IN1, IN2) representing sound in an environment of the user; • an output unit comprising an output transducer for providing stimuli perceivable to the user as sound based on said electric input signals (IN1, IN2) or a processed version thereof; • a spatial filter connected to said input unit and to said output unit, and configured to provide a spatially filtered signal (Y BF) based on said multitude of electric input signals (IN1, IN2) and configurable beamformer weights; • a loop gain estimator for estimating a current loop magnitude of a feedback loop defined by a forward path between the input unit and the output unit, and an external feedback path (h1, h2) from said output unit to said input unit, • a spatial filter controller configured to apply first and/or second different sets (w1p, w2p) of beamformer weights to said multitude of electric input signals (IN1, IN2) in dependence of said estimated current loop magnitude, wherein said first set (w1p) of beamformer weights is applied to provide spatial filtering of sound from said output transducer, and wherein said second set (w2p) of beamformer weights is applied to provide spatial filtering of an external sound field (S ENV).
A method of retrofitting a driveshaft lock to a vehicle, characterized in that the driveshaft lock includes: a rotor which defines a central aperture which is configured to receive a non-circular, peripheral profile of a drive flange of a driveshaft therethrough such that the rotor is configured to piggyback on the drive flange; a locking member which is configured selectively to engage the rotor in order to lock the rotor in position and prevent angular displacement thereof; the method including: aligning the central aperture of the rotor with the non-circular peripheral profile of the drive flange; passing the rotor over the drive flange; rotating the rotor relative to the drive flange so that the central aperture is out of register with the non-circular peripheral profile of the drive flange; and securing the rotor to the drive flange for rotation together with the drive flange, piggyback-style, about a drive axis. a rotor which defines a central aperture which is configured to receive a non-circular, peripheral profile of a drive flange of a driveshaft therethrough such that the rotor is configured to piggyback on the drive flange; a locking member which is configured selectively to engage the rotor in order to lock the rotor in position and prevent angular displacement thereof; the method including: aligning the central aperture of the rotor with the non-circular peripheral profile of the drive flange; passing the rotor over the drive flange; rotating the rotor relative to the drive flange so that the central aperture is out of register with the non-circular peripheral profile of the drive flange; and securing the rotor to the drive flange for rotation together with the drive flange, piggyback-style, about a drive axis. aligning the central aperture of the rotor with the non-circular peripheral profile of the drive flange; passing the rotor over the drive flange; rotating the rotor relative to the drive flange so that the central aperture is out of register with the non-circular peripheral profile of the drive flange; and securing the rotor to the drive flange for rotation together with the drive flange, piggyback-style, about a drive axis.
Tumble dryer comprising a drum that is rotatably mounted in a housing and, in its basic form, comprises a base module, heated process air being supplied to the drum, and the dryer being equipped with a heat pump device arranged in the base module, in which device coolant circulates in a circuit through an evaporator, a compressor, a condenser and a throttle device, the process air being guided over the condenser, a cooling fan being provided to cool the compressor, or the compressor and the coolant, the base module, as an assembly with the heat pump unit, comprising a box-shaped shaft in which the cooling fan for the compressor set on the base module can be placed, the shaft comprising an opening for receiving or for removing the cooling fan and being designed having open side walls and for the passage of the cooling air flow, characterised in that the opening of the shaft is oriented towards one side of the base module and in that the cooling fan comprises a box-shaped housing, which can be inserted into the shaft in a positive fit, resilient elements being arranged in the wall region of the shaft in order to mount the cooling fan so as to have zero clearance when inserted.
Insulin derivative with cyclic structure in the C-terminus of B-chain having formula I where DOI is des(B23-B30)octapeptide-insulin, and its pharmaceutically acceptable salts and solvates.
Polyphase transverse flux machine having a stator and a rotor which can be rotated relative to the stator about an axis in a circumferential direction, wherein the transverse flex machine comprises for a respective current phase: - an electrical line which runs along a multiplicity of yokes (3,3') in the circumferential direction, wherein the line and the multiplicity of the yokes (3,3') are provided in the stator; - a pair of permanent magnet arrays (5,5') which run in parallel in the circumferential direction and which each comprise a multiplicity of permanent magnets and are provided in the rotor; - a multiplicity of return path bodies (7,7') which are provided in the stator, wherein each yoke (3,3') is assigned a return path body (7,7') which is spaced apart from the associated yoke (3,3') in the radial direction; - wherein the magnetization direction of the permanent magnets in the permanent magnet arrays (5,5') changes in such a way that a closed magnetic flux repeatedly occurs at each yoke (3,3') during the rotation of the rotor, wherein the closed magnetic flux runs from one permanent magnet array (5,5') of the pair via a respectively yoke (3,3') to the other permanent magnet array (5,5') of the pair, and from there via the assigned return path body (7,7') back to the first-mentioned permanent magnet array (5, 5') of the pair, characterized in that - the respective return path bodies (7,7') are arranged between the permanent magnet arrays (5, 5') of the pair. - an electrical line which runs along a multiplicity of yokes (3,3') in the circumferential direction, wherein the line and the multiplicity of the yokes (3,3') are provided in the stator; - a pair of permanent magnet arrays (5,5') which run in parallel in the circumferential direction and which each comprise a multiplicity of permanent magnets and are provided in the rotor; - a multiplicity of return path bodies (7,7') which are provided in the stator, wherein each yoke (3,3') is assigned a return path body (7,7') which is spaced apart from the associated yoke (3,3') in the radial direction; - wherein the magnetization direction of the permanent magnets in the permanent magnet arrays (5,5') changes in such a way that a closed magnetic flux repeatedly occurs at each yoke (3,3') during the rotation of the rotor, wherein the closed magnetic flux runs from one permanent magnet array (5,5') of the pair via a respectively yoke (3,3') to the other permanent magnet array (5,5') of the pair, and from there via the assigned return path body (7,7') back to the first-mentioned permanent magnet array (5, 5') of the pair, characterized in that - the respective return path bodies (7,7') are arranged between the permanent magnet arrays (5, 5') of the pair.
A biopsy site marker, comprising: a carrier (520, 620... 1620); and a marker element (512, 612... 1612) disposed within the carrier (520, 620... 1620), the carrier (520, 620... 1620) including a first marker material (522, 622,... 1622) and a second marker material (524, 624,... 1624), characterized by the first marker material and the second marker material being each configured to expand in the presence of moisture, the first marker material being configured to expand at a rapid rate relative to the second marker material in the presence of moisture. a carrier (520, 620... 1620); and a marker element (512, 612... 1612) disposed within the carrier (520, 620... 1620), the carrier (520, 620... 1620) including a first marker material (522, 622,... 1622) and a second marker material (524, 624,... 1624), characterized by the first marker material and the second marker material being each configured to expand in the presence of moisture, the first marker material being configured to expand at a rapid rate relative to the second marker material in the presence of moisture.
A pharmaceutical composition for use in preventing, alleviating, or treating inflammation and/or pains, the pharmaceutical composition comprising: as an effective component, a first material selected from the group consisting of a fraction of the extract from Broussonetia papyrifera, and a pharmaceutically acceptable salt thereof; as an effective component, a second material selected from the group consisting of an extract from Lonicera japonica and a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the fraction of the extract from Broussonetia papyrifera is a prenylated flavonoid- enriched extract prepared by extracting Broussonetia papyrifera with ethanol, drying the extract under vacuum condition, and fractionating the extract using ethyl acetate, and the extract from Lonicera japonica is an ethanol extract. as an effective component, a first material selected from the group consisting of a fraction of the extract from Broussonetia papyrifera, and a pharmaceutically acceptable salt thereof; as an effective component, a second material selected from the group consisting of an extract from Lonicera japonica and a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the fraction of the extract from Broussonetia papyrifera is a prenylated flavonoid- enriched extract prepared by extracting Broussonetia papyrifera with ethanol, drying the extract under vacuum condition, and fractionating the extract using ethyl acetate, and the extract from Lonicera japonica is an ethanol extract.
A method for reducing the effect of interferent in a test for analyte concentration, comprising: (a) introducing a physiological sample into an electrochemical cell, the electrochemical cell comprising: (i) first and second electrodes (166, 164) in a spaced apart relationship; and (ii) a first reagent, the reagent comprising a mediator and an enzyme; (b) applying a first test potential having a first polarity to the cell and measuring cell current to obtain a first peak current value; (c) applying a second test potential having a second polarity and measuring cell current to obtain a second peak current value, wherein the first polarity is opposite to the second polarity; (d) calculating an interference correction factor based on the first and second peak current values, wherein the interference correction factor is used to reduce the influence of interferents in a glucose concentration calculation. (a) introducing a physiological sample into an electrochemical cell, the electrochemical cell comprising: (i) first and second electrodes (166, 164) in a spaced apart relationship; and (ii) a first reagent, the reagent comprising a mediator and an enzyme; (i) first and second electrodes (166, 164) in a spaced apart relationship; and (ii) a first reagent, the reagent comprising a mediator and an enzyme; (b) applying a first test potential having a first polarity to the cell and measuring cell current to obtain a first peak current value; (c) applying a second test potential having a second polarity and measuring cell current to obtain a second peak current value, wherein the first polarity is opposite to the second polarity; (d) calculating an interference correction factor based on the first and second peak current values, wherein the interference correction factor is used to reduce the influence of interferents in a glucose concentration calculation.
Combustion engine with an internal combustion engine which is provided with a gaseous fuel for operation and to which fresh gas can be supplied via a fresh gas line, with one or more fuel pressure tanks and with one or more gas injection valves which can be connected to the fuel pressure tank(s) via a pressure regulating device, a switching valve, wherein in a first switch position of the switching valve, the fuel can be routed to the gas injection valve(s) via a first feed line and, in a second switch position, can be routed into the fresh gas line via a second feed line bypassing the gas injection valve(s), characterized by a control device for automatically controlling the switching valve, wherein the control device is designed in such a way that a method according to any one of Claims 7 to 10 can be implemented by means of said control device.
An antibody anti-protective antigen of anthrax toxin comprising: - a Fc part of human origin, and: - either the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: H/L and S/G, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2 mutated on the following position: Q/L, - or the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: G/S, R/K and K/R, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2, the positions of amino acids being indicated on figure 1, and characterized in that said modified antibody has improved affinity relative to the nonmutated antibody. - a Fc part of human origin, and: - either the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: H/L and S/G, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2 mutated on the following position: Q/L, - or the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: G/S, R/K and K/R, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2, the positions of amino acids being indicated on figure 1, and characterized in that said modified antibody has improved affinity relative to the nonmutated antibody. - either the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: H/L and S/G, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2 mutated on the following position: Q/L, - or the variable region of the heavy chain of amino acid sequence represented by SEQ ID No.1 mutated on the following positions: G/S, R/K and K/R, and the variable region of the light chain of amino acid sequence represented by SEQ ID No.2,